April 7, 2026

Postmarketing Spontaneous Reporting Systems: the Backbone of Real-World Drug Safety Surveillance

Once a medicine reaches the market, its safety story is far from complete. Clinical trials are essential, but they are not designed to capture every adverse reaction that may emerge once a product is used in routine care, across broader populations, longer time periods, and more complex clinical settings. That is where postmarketing pharmacovigilance begins, and at the center of it sits the spontaneous reporting system, or SRS.¹

A spontaneous reporting system is a structured framework through which suspected adverse drug reactions are reported after a medicine has been authorized for use. These reports usually come from healthcare professionals, patients, pharmaceutical companies, or national regulatory bodies, and they are submitted without a predefined study protocol. The reports are typically stored as individual case safety reports, or ICSRs, which capture details about the patient, the suspected drug, the adverse event, and other clinically relevant context.²

Why postmarketing SRS matter

Pre-approval trials have unavoidable blind spots. They often involve relatively small numbers of carefully selected participants, limited follow-up, and exclusion of populations such as older adults, pregnant people, children, or patients with multiple comorbidities. As a result, rare adverse events, delayed toxicities, drug-drug interactions, and harms that occur only in particular subgroups may remain undetected until a drug is used at scale in the real world. Spontaneous reporting systems help close that gap by acting as early warning systems for emerging safety problems.¹

This is why SRS databases remain foundational in pharmacovigilance. The World Health Organization describes spontaneous reporting as the primary method in pharmacovigilance, and both FDA and EMA materials place adverse event report databases at the heart of postmarketing surveillance and signal identification.²³

What an SRS actually contains

At the core of an SRS are ICSRs. An individual report usually includes the suspected medicine, one or more reported adverse events, patient demographics, dates, reporter type, outcomes, and sometimes dose, route, indication, and concomitant products. In practice, the completeness of these fields varies widely, which is one reason SRS data are so valuable yet so challenging to interpret.⁴

Major postmarketing SRS infrastructures include national and international databases. In the United States, FAERS supports FDA’s postmarketing surveillance of drugs and therapeutic biologics. In the European Union, EudraVigilance is a major source for suspected adverse reaction monitoring and signal management. At the global level, the WHO Programme for International Drug Monitoring is coordinated by the Uppsala Monitoring Centre, which manages VigiBase, an international repository of ICSRs contributed by member countries.³⁵

From case reports to safety signals

A single spontaneous report doesn’t proves causality; what makes SRS powerful is accumulation. When similar reports begin to cluster around the same drug-event combination, that pattern may suggest a safety signal worthy of further assessment. A signal does not mean the medicine caused the event, only that the association deserves closer evaluation.⁶

Signal detection in SRS databases often combines clinical review with statistical screening. Regulatory and methodological guidance describes routine scanning of spontaneous reports to identify drug-event combinations that occur disproportionately often compared with the rest of the database. This family of methods is commonly called disproportionality analysis.⁷

Common disproportionality metrics include the proportional reporting ratio (PRR), reporting odds ratio (ROR), information component (IC), and empirical Bayes geometric mean (EBGM). These methods do not estimate incidence and they do not establish causation. Instead, they flag unusual reporting patterns that may indicate a potential risk requiring validation through clinical review, epidemiology, mechanistic assessment, or regulatory follow-up.⁷

Strengths of postmarketing SRS

The biggest strength of an SRS is reach. It can capture suspected harms across millions of exposed patients, long after product approval, and across diverse countries, healthcare settings, and patient subgroups. Because reporting continues throughout a product’s life cycle, SRS databases are particularly valuable for detecting rare, unexpected, or serious adverse reactions that would be difficult to identify in premarketing trials.¹

Another major advantage is speed. Spontaneous reporting can surface concerns early, sometimes before formal observational studies are feasible. This makes SRS especially important for early signal generation, label updates, risk minimization measures, and prioritization of further investigation.⁶

SRS data are also comparatively broad in scope. They can reveal safety patterns related to specific formulations, routes, medication errors, special populations, or real-world use scenarios that are often underrepresented during development.³

Limitations and interpretive caution

Despite their importance, spontaneous reporting systems have major limitations. Under-reporting is one of the most fundamental: many adverse reactions are never submitted at all. Reporting is also selective, influenced by publicity, litigation, novelty of the drug, seriousness of the event, regulatory attention, and reporter awareness. As a result, the number of reports in an SRS cannot be interpreted as the true frequency of an adverse event in the population.²

A second limitation is missing or inconsistent data. Fields such as indication, timing, dose, co-medications, and medical history may be incomplete, which complicates causal assessment and subgroup analysis. Duplicates, coding variability, and confounding by disease severity or co-treatment can further distort the picture. These are well-recognized methodological issues in pharmacovigilance and one reason regulatory frameworks emphasize signal validation rather than blind reliance on automated outputs.⁴

Most importantly, SRS databases usually lack a reliable denominator. We often do not know exactly how many people were exposed to the drug, for how long, or under what circumstances. That means spontaneous reports are excellent for signal detection, but weak for estimating absolute risk or incidence.⁸

The modern role of SRS in pharmacovigilance

Today, postmarketing SRS should not be viewed as a standalone solution, but as the first layer of a broader safety intelligence system. Regulatory guidance increasingly positions spontaneous reports alongside literature surveillance, clinical studies, electronic healthcare data, and targeted post-authorisation studies. In this model, SRS remains the hypothesis-generating engine: it identifies unusual patterns quickly, while other data sources help test, contextualize, and quantify them.⁶

This is especially relevant in an era of data mining and machine learning. Large repositories such as FAERS, EudraVigilance, and VigiBase allow statistical and computational screening at scale, but the core principle remains unchanged: a signal from spontaneous reports is a prompt for investigation, not a final answer.⁷

Final thoughts

Postmarketing spontaneous reporting systems remain the backbone of global pharmacovigilance. They are imperfect, noisy, and deeply vulnerable to bias, yet they are still one of the most powerful mechanisms for detecting emerging drug safety concerns in the real world. Their value lies not in proving causality or measuring incidence, but in making the invisible visible early enough for clinicians, regulators, and researchers to act.²

For that reason, SRS databases continue to play a central role in postmarketing surveillance: not because they are complete, but because they are often the first place where risk begins to announce itself.³

References

U.S. Food and Drug Administration. Introduction to Post-Marketing Drug Safety Surveillance. FDA. Available from: https://www.fda.gov/files/about%20fda/published/Introduction-to-Post-Marketing-Drug-Safety-Surveillance-%28PDF—1.46MB%29.pdf ↩ ↩² ↩³
World Health Organization, Uppsala Monitoring Centre. The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. Geneva: World Health Organization; 2002. Available from: https://who-umc.org/media/1703/24747.pdf ↩ ↩² ↩³ ↩⁴
U.S. Food and Drug Administration. FDA Adverse Event Monitoring System (AEMS). FDA. Available from: https://www.fda.gov/drugs/surveillance/fda-adverse-event-monitoring-system-aems ↩ ↩² ↩³ ↩⁴
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). EMA. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf ↩ ↩²
Uppsala Monitoring Centre. VigiBase. UMC. Available from: https://who-umc.org/vigibase/ ↩
European Medicines Agency. Signal management. EMA. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/signal-management ↩ ↩² ↩³
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module IX Addendum I – Methodological aspects of signal detection from spontaneous reports of suspected adverse reactions. EMA. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-addendum-i-methodological-aspects-signal-detection-spontaneous-reports-suspected-adverse-reactions_en.pdf ↩ ↩² ↩³
Alatawi YM, Hansen RA. Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2017;16(7):761-767. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12443087/ ↩

Back to blog